Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy

Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy

Objective: revealing the role of morphophenotypic indices in the development of visceral obesity in patients with schizophrenia receiving quetiapine and risperidone therapy.Materials and methods. 56 indoor patients with schizophrenia who received quetiapine (n = 23) or risperidone (n = 33) at medium...

Full description

Bibliographic Details
Main Authors:	E. G. Kornetova, V. V. Dubrovskaya, A. N. Kornetov, O. A. Lobacheva, S. A. Ivanova, A. V. Semke
Format:	Article
Language:	English
Published:	Siberian State Medical University (Tomsk) 2018-12-01
Series:	Bûlleten' Sibirskoj Mediciny
Subjects:	schizophrenia quetiapine risperidone visceral obesity noninvasive bioimpedancemetry
Online Access:	https://bulletin.tomsk.ru/jour/article/view/1978

Similar Items

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis
by: Yi-Ting Lin, et al.
Published: (2015-02-01)

Metabolic dysregulation in early onset psychiatric disorder before and after exposure to antipsychotic drugs
by: Rehmat Shah, et al.

Novos usos para medicações psicotrópicas conhecidas
by: Bisol, Luísa Weber
Published: (2008)

Novos usos para medicações psicotrópicas conhecidas
by: Bisol, Luísa Weber
Published: (2008)

Novos usos para medicações psicotrópicas conhecidas
by: Bisol, Luísa Weber
Published: (2008)

Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases
by: P K Pardal, et al.
Published: (2010-01-01)

Utilización de Neurolépticos atípicos en el Centro Penitenciario de Málaga Study of the use of atypical antipsychotic drugs in Málaga Prison
by: C. Salinas Rosillo, et al.
Published: (2007-06-01)

Bioimpedancemetry in Evaluating Nutritional Status of Patients with Chronic Inflammatory Bowel Diseases
by: Yu.M. Stepanov, et al.
Published: (2015-04-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Neuroleptic malignant syndrome induced by concomitant use of risperidone and quetiapine
by: Mustafa Volkan Demir, et al.
Published: (2016-01-01)

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
by: Giampaolo Perna, et al.
Published: (2016-04-01)

Comparative study on clinically latent aggressiveness inoutpatients with schizophrenia treated with classical antipsychotics and with risperidone
by: Konstantinos Tsirigotis, et al.
Published: (2014-03-01)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
by: Elena G. Kornetova, et al.
Published: (2020-09-01)

Comparison of tolerability between quetiapine and haloperidol in schizophrenia
by: Naba Raj Koirala, et al.
Published: (2012-12-01)

Sodium Valproate as an Adjunctive to Risperidone in Treatment of Schizophrenia
by: V Omrani Fard, et al.
Published: (2007-01-01)

Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
by: Maurizio Pompili, et al.
Published: (2016-10-01)

Evaluation of Clinical Outcome of Antipsychotic Therapy in Schizophrenic Patients in Palu - Indonesia
by: Astriana, et al.
Published: (2022)

Efficacy of ziprasidone and risperidone in treatment of vagrants with schizophrenia
by: Zhan-Hua Li, et al.
Published: (2016-06-01)

Efficacy and tolerability of clozapine versus quetiapine in treatment-resistant schizophrenia
by: Mitesh Kumar, et al.
Published: (2017-01-01)

PSYCHOMETRIC EVALUATION OF SYMPTOMS AND CLINICAL DYNAMICS OF SCHIZOPHRENIA IN DEPENDING ON CONSTITUTIONALLY-MORPHOLOGICAL TYPE OF THE PATIENTS
by: F. F. Mikilev, et al.
Published: (2016-06-01)

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
by: Firouzeh Raisi, et al.
Published: (2007-08-01)

Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
by: Firouzeh Raisi, et al.
Published: (2007-09-01)

Antipsychotic-associated psoriatic rash – a case report
by: Camelia-Eugenia Bujor, et al.
Published: (2017-07-01)

Functional Hallucinations in Schizophrenia Responding to Adjunctive Sodium Valproate
by: Ravi Philip Rajkumar
Published: (2012-01-01)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
by: Hong Jihyung, et al.
Published: (2012-12-01)

The Therapeutic Effectiveness of Risperidone on Negative Symptoms of Schizophrenia in Comparison with Haloperidol: A Randomized Clinical Trial
by: Arash Mirabzadeh, et al.
Published: (2014-07-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
by: P N Suresh Kumar, et al.
Published: (2016-01-01)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
by: Liang Y, et al.
Published: (2017-04-01)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function
by: Ying Yang, et al.

Effect of Ginkgo biloba, Risperidone and Biperiden regimen in chronic schizophrenia
by: Nikfarjam M (MD), et al.
Published: (2012-05-01)

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study
by: Kiss Alexander
Published: (2018-04-01)

Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive Urinalysis
by: Peta-Gaye L. Thomas-Brown, et al.
Published: (2018-07-01)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
by: Hikaru Hori, et al.
Published: (2018-03-01)

Risperidone associated paralytic ileus in schizophrenia
by: Parthasarathy Ramamourthy, et al.
Published: (2013-01-01)

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
by: Pandina Gahan, et al.
Published: (2012-06-01)

Quality of life of patients suffering from schizophrenia and treated with long-acting risperidone and paliperidone-palmitate
by: Mihajlović Filip, et al.
Published: (2018-01-01)

Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study
by: Takahiro Ito, et al.
Published: (2018-11-01)

Cannot write session to /tmp/vufind_sessions/sess_da2oo2lmn4jd83uhq3cn2t8fh0